July 20, 2023
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 July 20, 2023 Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors Capitalizes on “Knob” biologics (Picobodies TM ) for tumor targeting, extends partnership to include validated target, HER3 IND filing for…